- Report
- April 2026
- 140 Pages
Global
From €2726EUR$2,999USD£2,344GBP
€3635EUR$3,999USD£3,125GBP
- Report
- November 2025
- 185 Pages
Global
From €4090EUR$4,500USD£3,517GBP
- Report
- September 2026
- 195 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,509GBP
- Report
- September 2026
- 383 Pages
Global
From €5318EUR$5,850USD£4,572GBP
- Report
- August 2026
- 160 Pages
Global
From €3018EUR$3,320USD£2,595GBP
€3772EUR$4,150USD£3,243GBP
- Report
- May 2026
- 148 Pages
Global
From €3590EUR$3,950USD£3,087GBP
- Report
- October 2025
- 90 Pages
Global
From €4090EUR$4,500USD£3,517GBP
- Report
- September 2026
- 460 Pages
Global
From €4086EUR$4,495USD£3,513GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,509GBP
- Report
- September 2026
- 191 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,509GBP
- Report
- September 2026
- 206 Pages
Global
From €5318EUR$5,850USD£4,572GBP
- Report
- July 2026
- 115 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- July 2026
- 135 Pages
Global
From €4318EUR$4,750USD£3,712GBP
- Report
- November 2024
- 265 Pages
Global
From €3795EUR$4,175USD£3,263GBP
- Report
- July 2023
- 152 Pages
Global
From €4227EUR$4,650USD£3,634GBP
- Report
- June 2025
- 100 Pages
United States
From €5408EUR$5,950USD£4,650GBP

Minimal Residual Disease (MRD) Testing is a type of In Vitro Diagnostics (IVD) used to detect the presence of cancer cells in a patient's body. It is used to monitor the effectiveness of cancer treatments and to detect the recurrence of cancer. MRD testing is typically performed on a sample of bone marrow or peripheral blood, and can detect cancer cells at levels as low as one in a million. It is used to detect the presence of cancer cells in patients with leukemia, lymphoma, and multiple myeloma.
MRD testing is a rapidly growing market, driven by the increasing prevalence of cancer and the need for more accurate and sensitive diagnostic tests. The development of new technologies, such as next-generation sequencing and flow cytometry, has enabled more accurate and sensitive MRD testing.
Companies in the MRD testing market include Abbott, Agilent Technologies, Bio-Rad Laboratories, Becton Dickinson, and Roche Diagnostics. Show Less Read more